Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Ida NetterbergLena E Friberg

Abstract

Quantitative relationships between treatment-induced changes in tumor size and circulating tumor cell (CTC) counts, and their links to overall survival (OS), are lacking. We present a population modeling framework identifying and quantifying such relationships, based on longitudinal data collected in patients with metastatic colorectal cancer (mCRC) to evaluate the value of tumor size and CTC counts as predictors of OS. A pharmacometric approach (i.e., population pharmacodynamic modeling) was used to characterize the changes in tumor size and CTC count and evaluate them as predictors of OS in 451 patients with mCRC treated with chemotherapy and targeted therapy in a prospectively randomized phase III study (CAIRO2). A tumor size model of tumor quiescence and drug resistance was used to characterize the tumor size time-course, and was, in addition to the total normalized dose (i.e., of all administered drugs) in a given cycle, related to the CTC counts through a negative binomial model (CTC model). Tumor size changes did not contribute additional predictive value when the mean CTC count was a predictor of OS. Treatment reduced the typical mean count from 1.43 to 0.477 (HR = 3.94). The modeling framework was applied to explore wh...Continue Reading

References

Mar 1, 1979·Clinical Pharmacology and Therapeutics·L B SheinerJ Ham
Oct 27, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·W Jeffrey AllardLeon W M M Terstappen
Dec 7, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniel C DanilaHoward I Scher
Jul 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven J CohenNeal J Meropol
Oct 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Johann S de BonoDerek Raghavan
Feb 7, 2009·The New England Journal of Medicine·Jolien TolCornelis J A Punt
Mar 14, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S J CohenN J Meropol
Jul 2, 2009·Pharmaceutical Research·Klas J F PeterssonMats O Karlsson
Jul 29, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laurent ClaretRené Bruno
Oct 29, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J TolC J A Punt
Mar 26, 2011·Science·Christine L Chaffer, Robert A Weinberg
Jan 19, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jian-Mei HouCaroline Dive
Oct 3, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C AggarwalS J Cohen
May 8, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laurent ClaretRené Bruno
Oct 19, 2013·British Journal of Clinical Pharmacology·Brendan C BenderLena E Friberg
May 17, 2014·Journal of the National Cancer Institute·Brigitte RackUNKNOWN SUCCESS Study Group
Aug 15, 2014·CPT: Pharmacometrics & Systems Pharmacology·E L Plan
Aug 1, 2015·CPT: Pharmacometrics & Systems Pharmacology·D R MouldB Frame
Mar 13, 2016·Cancer Discovery·Catherine Alix-Panabières, Klaus Pantel
Apr 14, 2016·CPT: Pharmacometrics & Systems Pharmacology·UNKNOWN EFPIA MID3 WorkgroupS A G Visser
Jul 7, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Van CutsemD Arnold
Aug 27, 2016·BioMed Research International·Daniela RodriguesSandra F Martins
Nov 9, 2016·Translational Lung Cancer Research·Silvia Calabuig-FariñasCarlos Camps
Nov 25, 2016·CPT: Pharmacometrics & Systems Pharmacology·T H T NguyenUNKNOWN Model Evaluation Group of the International Society of Pharmacometrics (ISoP) Best Practice Committee
Feb 27, 2017·International Journal of Clinical Oncology·Luc CabelFrançois-Clément Bidard
Apr 6, 2017·CPT: Pharmacometrics & Systems Pharmacology·E SchindlerL E Friberg
Aug 19, 2017·Theranostics·Lichan ChenZigang Dong
Apr 25, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Laurent ClaretRené Bruno
Jul 7, 2018·Computational and Structural Biotechnology Journal·Martin H D NeumannThomas Schlange
Sep 27, 2018·CPT: Pharmacometrics & Systems Pharmacology·Ron J KeizerSrijib Goswami
Oct 24, 2018·International Journal of Cancer. Journal International Du Cancer·J FerlayF Bray
Mar 13, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Saskia LitièreUNKNOWN RECIST Working Group
May 31, 2019·Nature·Stephen CristianoVictor E Velculescu
Feb 1, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C AggarwalS J Cohen

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Related Papers

Advances in Experimental Medicine and Biology
Costanza Paoletti, Daniel F Hayes
© 2022 Meta ULC. All rights reserved